TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21621660

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active Exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Passive Treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Education Booklet)
Number of subjects: 60
Study: 19817313

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study: 17033604

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 3x300 mg before reperfusion, and 8 and 16 h after reperfusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: NaCl 0.9% 3x100 mL
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 23
Study: 12589529

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (100 mg/kg intratracheally under continuous ventilation and PEEP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonsurfactant treatment
Number of subjects: 35
Study: 11778187

Group type: EXPERIMENTAL
Intervention: Microwave heating and bandaging treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (10 healthy volunteers)
Number of subjects: 27
Study: 9234031

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) supplementation (1 g per day for two weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 8
Study: 8384948

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (2.5 MJ)
Number of subjects: 0
Study: 3941213

Group type: EXPERIMENTAL
Intervention: OKY‐046, 400 mg/day orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30125761

Group type: EXPERIMENTAL
Intervention: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC)
Number of subjects: 664

Group type: COMPARATOR
Intervention: docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC)
Number of subjects: 664
Study: 26649909

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB) with 30 mL ropivacaine 0.75% at t0 and 30 mL saline at t60
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group received saline first followed by ACB
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 25022831

Group type: EXPERIMENTAL
Intervention: Inpatient treatment (6 months of hospitalization on working days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ambulatory treatment (12 days of hospital visits over 6 months)
Number of subjects: 90
Study: 22906138

Group type: EXPERIMENTAL
Intervention: Climate Schools only
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Preventure only
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CAP (Climate Schools and Preventure)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (alcohol, drug and health education as usual)
Number of subjects: 27
Study: 20233850

Group type: COMPARATOR
Intervention: Control group (no scheduled mammography)
Number of subjects: 3706
Study: 17055227

Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Enriched Supportive Therapy (Control)
Number of subjects: 38
Study: 15867204

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab 375 mg/m² + CHOP)
Number of subjects: 399
Study: 12641015

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 283
Study: 9705024

Group type: EXPERIMENTAL
Intervention: 5-HTP (750 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8539554

Group type: EXPERIMENTAL
Intervention: Higher antigen content vaccine (20 micrograms pertussis toxoid and 20 micrograms filamentous hemagglutinin)
Number of subjects: 2050

Group type: EXPERIMENTAL
Intervention: Lower antigen content vaccine (10 micrograms pertussis toxoid and 5 micrograms filamentous hemagglutinin)
Number of subjects: 2050

Group type: COMPARATOR
Intervention: Both vaccine formulations
Number of subjects: 2050
Study: 2181857

Group type: EXPERIMENTAL
Intervention: Silicone-rubber balloon inflated with 400 mL for 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Silicone-rubber balloon deflated for 1 month
Number of subjects: 10
Study: 391622

Group type: EXPERIMENTAL
Intervention: Inositol nicotinate (Hexopal)
Number of subjects: 30
Study: 31630916

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided insertion (US)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anatomical landmark insertion (LM)
Number of subjects: 100
Study: 29283929

Group type: EXPERIMENTAL
Intervention: 5 sets of 10 repetitions at 30% of 1 repetition maximum (1RM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 sets of 5 repetitions at 70% of 1RM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 sets of 3 repetitions at 90% of 1RM
Number of subjects: 9
Study: 27304455

Group type: EXPERIMENTAL
Intervention: Caregiver reflections on asthma home and community management
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 13
Study: 25541015

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGFs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no PRGFs)
Number of subjects: 15
Study: 22973855

Group type: EXPERIMENTAL
Intervention: Planning for five minutes
Number of subjects: 160

Group type: COMPARATOR
Intervention: No interruption and no planning
Number of subjects: 160

Group type: COMPARATOR
Intervention: Interruption but no planning
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Planning but no interruption
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both planning and interruption
Number of subjects: 160
Study: 21349484

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 2 days before PCI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Immediate PCI (Control group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Registry group (long-term statin therapy)
Number of subjects: 200
Study: 18834910

Group type: EXPERIMENTAL
Intervention: MenACWY-TT formulations
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MenACWY-TT formulation (specific formulation lower for serogroup A)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Licensed ACWY polysaccharide vaccine
Number of subjects: 175
Study: 15719071

Group type: EXPERIMENTAL
Intervention: 0.07% high bioavailable, alcohol-free CPC rinse
Number of subjects: 55

Group type: COMPARATOR
Intervention: Listerine Cool Mint containing essential oils
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo CPC rinse
Number of subjects: 55
Study: 12096085

Group type: EXPERIMENTAL
Intervention: Anethole dithiolethione (ADT) at 25 mg orally thrice daily for 6 months
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Anethole dithiolethione (ADT)
Number of subjects: 112
Study: 10625850

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride 0.15% oral mouthwash 3 times a day for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo 3 times a day for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 7793209

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg orally)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ibuprofen and Codeine (800 mg ibuprofen + 60 mg codeine orally)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 1942288

Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg per day
Number of subjects: 10
Study: 7024020

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) after 3 weeks of treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both CIT and CSII
Number of subjects: 8
Study: 31284737

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 7618

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 7618
Study: 28054436

Group type: EXPERIMENTAL
Intervention: Caffeine (60 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (soymilk powder)
Number of subjects: 95
Study: 25726088

Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study: 25139268

Group type: EXPERIMENTAL
Intervention: Propofol in monosedation
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combination of propofol + meperidine
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combination of midazolam + meperidine
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Other combinations
Number of subjects: 307

Group type: COMPARATOR
Intervention: All sedation types
Number of subjects: 307
Study: 22748356

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1710

Group type: COMPARATOR
Intervention: eptifibatide
Number of subjects: 1710
Study: 19773623

Group type: EXPERIMENTAL
Intervention: TVT (tension-free vaginal tape)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: TVT-O (tension-free vaginal tape obturator)
Number of subjects: 264
Study: 17449994

Group type: EXPERIMENTAL
Intervention: Temporary tattoo of a pain intensity scale (TTPS)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Paper version of the pain scale (PPS)
Number of subjects: 111
Study: 14981104

Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic mastectomy
Number of subjects: 483

Group type: COMPARATOR
Intervention: No bilateral prophylactic mastectomy (matched controls)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic mastectomy with prior or concurrent bilateral prophylactic oophorectomy
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic mastectomy with intact ovaries
Number of subjects: 483
Study: 11751030

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10518867

Group type: EXPERIMENTAL
Intervention: Baking soda dentifrices with Zn++
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baking soda dentifrices (20% and 30%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dentifrice containing 65% baking soda
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard dentifrice containing 0.76% sodium monofluorophosphate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Baking soda toothpastes
Number of subjects: 11
Study: 7863474

Group type: EXPERIMENTAL
Intervention: n-3 PUFA ethyl esters (4 x 1 g capsules)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil (4 x 1 g capsules, placebo)
Number of subjects: 20
Study: 2491454

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg at night)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ranitidine (150 mg at night)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Famotidine and Ranitidine
Number of subjects: 143
Study: 60091

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30064718

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 1-7 mg/day; morning administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25115324

Group type: EXPERIMENTAL
Intervention: Drain placement
Number of subjects: 761

Group type: COMPARATOR
Intervention: No drain placement
Number of subjects: 761
Study: 23471362

Group type: EXPERIMENTAL
Intervention: Parent-based interdisciplinary intervention for mothers
Number of subjects: 52
Study: 21515017

Group type: EXPERIMENTAL
Intervention: Arm-ergometry training (n = 10)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Treadmill training (n = 10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual-care control group (n = 8)
Number of subjects: 28
Study: 18373710

Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg weekly for 3 months
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg weekly for up to 33 months
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Efalizumab (dosage not specified) during the optional transition period
Number of subjects: 339
Study: 17136942

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation containing essential vitamins plus quercetin (FRS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline time trial (B)
Number of subjects: 11
Study: 12954742

Group type: EXPERIMENTAL
Intervention: PYY infusion
Number of subjects: 24
Study: 10823256

Group type: EXPERIMENTAL
Intervention: Fixed dose subcutaneous LMWH Certoparin (8,000 anti-factor Xa U b.i.d.)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Adjusted dose intravenous UFH
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Fixed dose subcutaneous LMWH Certoparin
Number of subjects: 538
Study: 8965385

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study: 1797193

Group type: EXPERIMENTAL
Intervention: 30 mg/m2 epirubicin weekly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 90 mg/m2 epirubicin every 3 weeks
Number of subjects: 40
Study: 6344649

Group type: EXPERIMENTAL
Intervention: Antibiotic-steroid otic drops at the time of surgery and for 1 week afterward
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Oral ampicillin for 24 hours preceding and 3 days following surgery
Number of subjects: 107

Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 107
Study: 31982075

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg/day for 1 week, increasing to 50 mg/day for up to 12 months) plus usual care
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo plus usual care
Number of subjects: 114
Study: 30775982

Group type: EXPERIMENTAL
Intervention: Couple-based interdisciplinary psychosocial intervention (7 sessions at home)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Couple-based interdisciplinary psychosocial intervention
Number of subjects: 108
Study: 29221496

Group type: EXPERIMENTAL
Intervention: Intensive management involving monthly clinical reviews and individualised treatment support
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard care following local pathways and NICE guidelines
Number of subjects: 398
Study: 26022006

Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study: 24308806

Group type: EXPERIMENTAL
Intervention: Self-assessment without tailored feedback
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Self-assessment with tailored feedback
Number of subjects: 178

Group type: COMPARATOR
Intervention: Generic information only
Number of subjects: 178
Study: 22946768

Group type: EXPERIMENTAL
Intervention: Weekly pursed-lips breathing (PLB) reinforcement sessions via Skype for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group received PLB instruction at baseline only
Number of subjects: 22
Study: 19341357

Group type: EXPERIMENTAL
Intervention: Combination of lecture and simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture only (Control)
Number of subjects: 0
Study: 17617281

Group type: EXPERIMENTAL
Intervention: Codeine/acetaminophen (C/A) 30/500 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen (H/A) 5/500 mg
Number of subjects: 121
Study: 15339497

Group type: EXPERIMENTAL
Intervention: Jianwei Yuyang Granules (JWYY group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine (control group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal control group (n=10)
Number of subjects: 60
Study: 11757699

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy supported by autologous blood stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized neuropsychological testing and quality-of-life assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy delay in complete responders to chemotherapy
Number of subjects: 0
Study: 11408793

Group type: EXPERIMENTAL
Intervention: DA agonist (lisuride 0.2 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DA antagonist (fluphenazine 2 mg)
Number of subjects: 36
Study: 9260011

Group type: COMPARATOR
Intervention: Neostigmine 10 micrograms.kg-1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neostigmine 20 micrograms.kg-1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms.kg-1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups (including neostigmine and placebo)
Number of subjects: 100
Study: 8291866

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy with doxorubicin (ADM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy with mitomycin C (MMC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravesical immunotherapy with bacillus Calmette-Guérin (BCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant prophylactic instillation treatments (local cytostatics and immunoagents)
Number of subjects: 0
Study: 3548315

Group type: COMPARATOR
Intervention: Mitomycin and Doxorubicin (MA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mitomycin, Doxorubicin, and Cisplatin (MAP)
Number of subjects: 55
Study: 29306990

Group type: EXPERIMENTAL
Intervention: Peer navigation and education intervention
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 348
Study: 26729884

Group type: EXPERIMENTAL
Intervention: Anticonflict intervention encouraging public stance against conflict
Number of subjects: 24191

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 24191
Study: 25046667

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both ECTR and OCTR
Number of subjects: 25
Study: 22471131

Group type: EXPERIMENTAL
Intervention: Acupuncture at starting and ending points of trapezius (Tianzhu (BL 10), Fengchi (GB 20), Quyuan (SI 13), Jugu (LI 16), Ashi)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture at Jiaji (EX‐B 2) points
Number of subjects: 60
Study: 19854614

Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl anesthesia
Number of subjects: 140

Group type: COMPARATOR
Intervention: Midazolam-fentanyl anesthesia
Number of subjects: 140
Study: 19167595

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 143

Group type: COMPARATOR
Intervention: Celecoxib 200 mg/d
Number of subjects: 143
Study: 15669897

Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 14700102

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%-lidocaine 2% mixture
Number of subjects: 32
Study: 10562789

Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional blind placement
Number of subjects: 30
Study: 8685930

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Maprotiline (150 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 2060201

Group type: EXPERIMENTAL
Intervention: Core decompression
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 36
Study: 29658455

Group type: EXPERIMENTAL
Intervention: Early intervention via fiber bronchoscope (≤3 days)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Late intervention via fiber bronchoscope (>3 days)
Number of subjects: 96
Study: 26333596

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 1116
Study: 25458650

Group type: EXPERIMENTAL
Intervention: Vorapaxar with clopidogrel
Number of subjects: 12887

Group type: EXPERIMENTAL
Intervention: Vorapaxar without clopidogrel
Number of subjects: 12887
Study: 22380768

Group type: EXPERIMENTAL
Intervention: Transcutaneous electric acupoint stimulation (TEAS) administered at bilateral P6 acupoint for 30 min after basal anesthesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (an electrode placed on the arm without stimulus)
Number of subjects: 70
Study: 20113455

Group type: EXPERIMENTAL
Intervention: Predonation water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predonation water and leg exercise during donation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (leg exercise before venipuncture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard donation
Number of subjects: 0
Study: 18220081

Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release 12.5 mg
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study: 16820548

Group type: EXPERIMENTAL
Intervention: Varenicline, 1 mg twice per day (n = 603)
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Placebo (n = 607)
Number of subjects: 1210
Study: 14584721

Group type: EXPERIMENTAL
Intervention: Experimental mouth rinse A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental mouth rinse B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control mouth rinse
Number of subjects: 0
Study: 10983675

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crystalloid medium
Number of subjects: 0
Study: 9181646

Group type: EXPERIMENTAL
Intervention: Alternating treatment with zidovudine 600 mg/day and didanosine 400 mg/day
Number of subjects: 552

Group type: COMPARATOR
Intervention: Zidovudine 600 mg/day
Number of subjects: 552

Group type: COMPARATOR
Intervention: Didanosine 400 mg/day
Number of subjects: 552